Benzinga · Aug 10, 2026
HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:SRZN) with a Buy and maintains $44 price target.
SR
NASDAQ · SRZN
Surrozen, Inc.
Healthcare · Biotechnology
$24.01
Up+$0.30 (+1.27%)
Updated Aug 28, 2026, 12:58 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 201.6M
- P/E ratio
- -12.03
- Dividend yield
- 0.00%
- 52-week range
- $10.73 – $35.00
- Volume
- 340.75K
- Avg. volume
- 63.79K
Price performance
SRZN price history
1M range · 0 trading sessions · Daily adjusted prices
SRZN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest SRZN news
The latest Smart Investors Daily articles mentioning SRZN.
Stock researchCompany · Overview
SRZN research
Overview
Company profile and research snapshot.
Company profile
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $38.50
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | William Blair | Outperform | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 7, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2026 | TD Cowen | Buy | — |
| Mar 24, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 19, 2026
Cantor Fitzgerald Initiates Coverage On Surrozen with Overweight Rating, Announces Price Target of $40
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Surrozen (NASDAQ:SRZN) with a Overweight rating and announces Price Target of $40.
Yahoo · Nov 25, 2025
Surrozen to Present at Upcoming Healthcare Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences. 37th Annual Piper Sandler Healthcare Conference on December 2, 2025Surrozen Fireside Discussion at 6:30 AM Pacific Time/9:30 AM Eastern T
globenewswire.com · Nov 25, 2025
Surrozen to Present at Upcoming Healthcare Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
